A Study to Quantify Tumour Perfusion for Spine Metastasis Treated With Stereotactic Body Radiotherapy (SBRT)

N

National University Health System (NUHS)

Status

Unknown

Conditions

Spine Metastasis

Treatments

Radiation: Stereotactic body radiotherapy

Study type

Observational

Funder types

Other

Identifiers

NCT03072979
2016/01179

Details and patient eligibility

About

Pre-clinical evidence suggests that radiotherapy reduces tumour-associated vasculature. The investigators will conduct a single-arm prospective study to quantify the reduction in tumour vasculature post-radiotherapy

Enrollment

18 estimated patients

Sex

All

Ages

21+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age ≥21 years of age
  • Proven metastatic disease, excluding haematological and germ cell neoplasms
  • Life expectancy >3 months, Eastern Cooperative Oncology group (ECOG) 0-2

Exclusion criteria

  • The patient must not have an allergy to gadolinium contrast that will limit the ability to image the tumour by MRI safely even with the use of premedication
  • eGFR < 30 mL/min or if patient is suffering from acute renal insufficiency
  • Prior radiotherapy to the specified region
  • Recent surgery to affected spinal levels, or patients requiring immediate surgical intervention
  • Spinal instability score (SINS) >12
  • Symptomatic cord compression (Bilksy grade 2 or 3), or worsening neurological deficits
  • Body weight of more than 120kg
  • Pregnancy

Trial contacts and locations

0

Loading...

Central trial contact

BALAMURUGAN VELLAYAPPAN, MBBS, FRANZCR

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems